This page describes pharmacological agents that may have legal restrictions, side effects, and drug interactions in your jurisdiction. Information is for educational research only — consult a clinician before considering any compound.
Metformin
The original "longevity drug" candidate and still the most-discussed one in the field — but the 2024-2025 evidence has softened the case rather than firming it up.
Aliases (5)
Overview
What is Metformin?
Metformin is an oral biguanide and the first-line pharmacotherapy for type 2 diabetes. It is widely used off-label for PCOS, insulin resistance, and longevity research.
Key Benefits
Lowers fasting glucose and HbA1c without hypoglycemia, improves insulin sensitivity, supports modest weight loss and PCOS symptom control, and is studied for cardiovascular and longevity benefits in non-diabetic populations.
Mechanism of Action
Inhibits mitochondrial complex I, raising the AMP/ATP ratio and activating AMPK. AMPK suppresses hepatic gluconeogenesis, lowers lipogenesis, and improves peripheral glucose uptake. Also alters gut microbiota and bile-acid handling.
Pharmacokinetics
Peptide Interactions
Mandatory for chronic users. Non-negotiable. Hydroxocobalamin injection (1000mcg IM monthly) is the gold standard for documented deficiency.
Offsets homocysteine elevation from B12/folate disruption. The user already takes P5P 100mg in V4 stack — that's the right idea.
Standard combination in T2D. Additive glycemic control. Different mechanisms (incretin-mimetic vs hepatic glucose output reduction). The metformin + GLP-1 co…
Different glycemic mechanism (renal glucose excretion). Can stack; modern T2D combination therapy.
Different mechanisms; can stack.
Both inhibit mTOR via different routes (rapamycin direct mTORC1 binding; metformin upstream via AMPK). Some longevity practitioners stack low-dose metformin …
Neutral co-administration; all in Dylan's V4 stack, all safe.
Hold 48 hours pre/post for contrast CT. Risk: contrast-induced AKI → metformin accumulation → lactic acidosis. Standard radiology protocol.
Increases lactic acidosis risk via hepatic lactate buildup. Chronic heavy drinking is a relative contraindication; binge drinking on metformin is a hard "no."
Hypoglycemia risk multiplicative.
Both AMPK activators. Stacking is mostly redundant — pick one. Berberine is the OTC alternative when sourcing metformin is hard or for those wanting to avoid…
Konopka/Walton mechanism shows blunted adaptation. Not a "dangerous" interaction but a counterproductive one for performance athletes. Dylan's MMA + lifting …
What to Expect
- Week 1Tolerability and dose-response.
- Week 2-4Early effect window.
- Week 4-8Peak benefit assessment.
- Week 8+Cycle decision point.
Side Effects & Safety 6
Side Effects
- 1GI upset (nausea, bloating, loose stools, metallic taste, mild reflux) — ~20-30% experience some GI symptom in first month. Mitigations: titrate slowly (500mg → 1000mg over 1-2 weeks → 1500mg+ if needed), use XR formulation, dose with food, split into BID. Symptoms usually resolve within 4 weeks; if not, dose-reduce or discontinue.
- 2Mild weight loss (1-3 kg over 6-12 months) — usually viewed as a benefit in T2D/pre-diabetes; may be unwanted in lean athletes.
- 3Vitamin B12 deficiency on chronic use — cumulative risk; clinically significant after 4-5 years. Mechanism: metformin reduces calcium-dependent B12 absorption in the ileum. The 2024 Atkinson mini-systematic review (PMID 39526048) pooled 21 studies — 17/21 confirmed significant B12 depletion. Long-term users (≥4 years) have 67% higher likelihood of B12 deficiency than non-users. Risk rises ~3% per year of metformin exposure.
- 4Folate decrease (mild, secondary)
- 5Mild homocysteine elevation — due to B12/folate disruption of methylation cycle. Cardiovascularly relevant if uncorrected.
- 6Mild taste disturbances, dry mouth
When to Stop
- Lactic acidosis (MALA — metformin-associated lactic acidosis): Historical concern inherited from phenformin (withdrawn 1977 for high lactic-acidosis rate; phenformin's lipophilicity drove it). Metformin's risk is genuinely low — 3-9 cases per 100,000 patient-years, and almost always in renal insufficiency (eGFR <30), severe hypoxia (sepsis, CHF decompensation), acute liver failure, or iodinated-contrast-induced AKI. Mortality of MALA when it occurs is high (~30-50%); rarity of occurrence keeps the population risk low. Hold metformin 48 hours before/after iodinated contrast in radiology procedures. Hold during acute illness with hypoperfusion (sepsis, GI surgery, severe gastroenteritis).
- Hypoglycemia — rare as monotherapy in non-diabetics (metformin doesn't cause hypoglycemia alone — it inhibits hepatic glucose output rather than driving insulin secretion). Risk rises substantially when combined with sulfonylureas/insulin.
- Lactate sensitivity in athletes — theoretical: heavy anaerobic loads (MMA grappling rounds, sprint intervals) generate lactate; metformin's mild lactate-clearance impairment may shift threshold subtly. Not well-quantified.
- First 2-4 weeks: GI tolerability. Titrate slowly.
- First 3 months: Establish baseline B12, folate, homocysteine before starting; recheck at 3 months on novel use.
- Annually thereafter on chronic use: B12 + folate + homocysteine, HbA1c + lipids + eGFR + creatinine.
- Hold periods: Iodinated contrast CT (48 hr before/after), major surgery, severe acute illness with hypoperfusion risk, alcohol binges.
References
UK Prospective Diabetes Study Group, 1998 — Lancet: UKPDS 34 — Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes
36% all-cause mortality reduction; foundational T2D evidence
View StudyDiabetes Prevention Program Research Group, 2002 — NEJM: Reduction in incidence of type 2 diabetes with metformin or lifestyle intervention
DPP foundational pre-diabetes RCT, 31% reduction
View StudyHeckman-Stoddard, Crandall et al., 2025 — Cancer Prev Res: Randomized Study of Metformin and Intensive Lifestyle on Cancer Incidence over 21 Years in DPP
DPP 21-year cancer follow-up, no benefit
View StudyBannister et al., 2014 — Diabetes Obes Metab: Can people with type 2 diabetes live longer than those without?
UK CPRD observational, sparked TAME hypothesis
View StudyBarzilai et al., 2016 — Cell Metabolism: Metformin as a tool to target aging
TAME-rationale paper
View StudyKeys et al., 2025 — Ageing Research Reviews: Emerging uncertainty on the anti-aging potential of metformin
critical methodological review; weakens the longevity case
View StudyKonopka et al., 2019 — Aging Cell: Metformin inhibits mitochondrial adaptations to aerobic exercise training in older adults
exercise-blunting RCT (aerobic)
View StudyWalton et al., 2019 — Aging Cell: Metformin blunts muscle hypertrophy in response to progressive resistance exercise training in older adults — MASTERS trial
exercise-blunting RCT (resistance)
View StudyAtkinson, Gharti, Min, 2024 — touchREV Endocrinol: Metformin Use and Vitamin B12 Deficiency in T2D — risk factors mini-systematic review
B12 depletion meta-analysis
View StudyMadiraju et al., 2014 — Nature: Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase
alternative mGPDH mechanism
View StudyTAME Trial registry (ClinicalTrials.gov NCT04482426)
Targeting Aging with Metformin
View StudyAmerican Federation for Aging Research — TAME Trial
TAME programmatic context, funding updates
View StudyLatest research
- reviewEmerging uncertainty on the anti-aging potential of metformin (Ageing Research Reviews)Keys, Hallas, Miller, Suissa, Christensen — high-profile 2025 review critically re-examines Bannister-era observational signals and post-Konopka replication attempts; concludes the anti-aging case for metformin in non-diabetics has weakened, not strengthened, with newer data. Single most important update since the original V5 lock.
- rctDPP 21-year cancer incidence — no benefit from metformin or lifestyle (Cancer Prevention Research)Heckman-Stoddard, Crandall et al. — 3,234 pre-diabetic adults followed 21 years. Cancer incidence 9.8 (metformin) vs 10.8 (placebo) per 1,000 person-years; HR 0.90, NS. Combined with earlier DPP/DPPOS mortality null (no all-cause or CV mortality benefit), the long-run RCT signal in non-diabetic high-risk adults is essentially negative.
- meta-analysisMetformin use and vitamin B12 deficiency — risk factors (touchREV Endocrinol mini-systematic review)Atkinson, Gharti, Min — 21 articles pooled. 17/21 found significant B12 depletion on chronic metformin; risk scales with dose, duration, age, and ethnicity. Cements the B12 + homocysteine surveillance protocol on chronic use.
How was your experience with this compound?
Anonymous · one vote per session · results below at 5+ votes.
See something off?
Most of this wiki is AI-generated. Suggest a correction, dosing update, or new evidence — we review every submission.